Radiopharm Theranostics Limited
RADXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRadiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet. With a market capitalization of $14.7M, it sits in micro-cap territory. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Market Cap
$14.7M
Beta
0.86
P/E (TTM)
—
P/E (Fwd)
-0.44
EPS (TTM)
$-3.64
EPS (Fwd)
$-2.32
ROE
-174.7%
ROA
-45.1%
Cash
$4.1M
Total Debt
$0
Free CF
-$31.1M
52W Change
-80.8%
Annual Financials
Cash vs Debt
Where RADX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, RADX finished 72.41% below its 150-day moving average ($3.48) and 75.13% below its 200-day moving average ($3.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RADX overbought or oversold?
At the October 20, 2026 close, RADX's RSI(14) was 21.5, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Radiopharm Theranostics Limited reports $4.1M in cash and $0 in total debt. Free cash flow is running at -$31.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -174.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $292K (2023) to $2.8M (2026), reflecting a 847% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RADX.